An international trial led by University College London and the London School of Hygiene & Tropical Medicine reported that an AI system can improve radiotherapy planning for cervical and prostate cancers, supporting faster and more consistent treatment plan generation. The study was presented as evidence of practical clinical utility of AI in life-saving radiation treatment workflows, especially where planning resources are constrained. The report frames the technology as acting in planning stages, where AI can assist dose and target planning decisions. While radiotherapy remains clinician-directed, plan quality and time are key bottlenecks in many low- and middle-income settings. For oncology operations, AI-assisted planning can affect throughput for radiation oncology departments and may reduce variability that can occur between planner teams. The trial’s international framing also suggests a focus on scalability beyond single-institution experience. The key near-term question will be how regulators and payers evaluate AI-involved planning—whether as clinical decision support with defined guardrails or as an aspect of treatment delivery that requires broader validation under real-world conditions.